Trial result
HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial
In a phase 1 trial of 42 healthy adults, single oral doses of HOPO 14-1 up to 7500 mg caused no serious adverse events or dose-limiting toxicity. It is the first shelf-stable, broad-spectrum actinide chelator that does not require intravenous access or trained personnel.
Moves tractabilityS-tier: Nuclear stability
JAMA · 10.1001/jama.2026.19809